DEER PARK, Ill., Nov. 12, 2025 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team will host 1×1 meetings at the 16th Annual Craig-Hallum Alpha Select Conference being held November 18, 2025 in New York, NY. To schedule a 1×1 meeting with the Company, please contact your Craig-Hallum institutional sales representative. About Eton Pharmaceuticals Investor Relations: Source: Eton Pharmaceuticals.
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eight commercial rare disease products: KHINDIVI(TM), INCRELEX(R), ALKINDI SPRINKLE(R), GALZIN(R), PKU GOLIKE(R), Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has five additional product candidates in late-stage development: ET-600, Amglidia(R), ET-700, ET-800 and ZENEO(R) hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
